Study details
Enrolling now
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001
Iovance Biotherapeutics, Inc.
NCT IDNCT05361174ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
53
Study length
about 4.9 years
Ages
18–70
Locations
10 sites in CA, FL, KS +5
About this study
This trial is testing a treatment called IOV-4001 in adults with melanoma or advanced non-small cell lung cancer. The goal is to see if this treatment is effective and safe.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive IOV-4001
PhasePhase 1/Phase 2
Primary goalPhase 2: Objective Response Rate (ORR)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Phase 2: Objective Response Rate (ORR)
Secondary: CR Rate, Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), Progression-free Survival (PFS), Safety and Tolerability of IOV-4001
Body systems
Oncology